Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Arterial Sealing · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Arterial Sealing | DEVICE | - |
Inclusion Criteria: * The subject is 18 years of age or older * The subject is undergoing a diagnostic or interventional endovascular procedure via a retrograde femoral arterial access * The subject is willing and able to provide appropriate informed consent * The subject is willing and able to com...
Arterial Sealing is an investigational therapy being studied for hemostasis of arterial punctures, meaning it is intended to stop bleeding at the site where an artery has been punctured. It is being evaluated in a Phase 3 clinical trial for this purpose.
Arterial Sealing is being developed by Teleflex Incorporated, a company traded on the New York Stock Exchange under the ticker symbol TFX. Teleflex is conducting clinical research on this product for achieving hemostasis at arterial puncture sites.
Arterial Sealing is in Phase 3 clinical development. It is an investigational product and has not been approved by regulatory authorities. The Phase 3 trial has been completed, and the product remains under investigation for its safety and efficacy.
Arterial Sealing has one completed Phase 3 clinical trial registered under the identifier NCT00388284. The trial, titled "Safety and Efficacy Study Comparing Thrombin for Arterial Sealing," enrolled 270 participants in the United States and evaluated the product for achieving hemostasis of arterial punctures.
Arterial Sealing is being studied in comparison with thrombin, but it is not stated to be the same as thrombin. The clinical trial NCT00388284 is designed to compare the safety and efficacy of Arterial Sealing against thrombin for achieving hemostasis of arterial punctures.